James Yates

5.9k total citations · 1 hit paper
152 papers, 3.6k citations indexed

About

James Yates is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, James Yates has authored 152 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 30 papers in Oncology and 20 papers in Pharmacology. Recurrent topics in James Yates's work include Pharmacogenetics and Drug Metabolism (19 papers), Mathematical Biology Tumor Growth (17 papers) and Cancer Genomics and Diagnostics (14 papers). James Yates is often cited by papers focused on Pharmacogenetics and Drug Metabolism (19 papers), Mathematical Biology Tumor Growth (17 papers) and Cancer Genomics and Diagnostics (14 papers). James Yates collaborates with scholars based in United Kingdom, United States and Singapore. James Yates's co-authors include Waldemar Karwowski, Darren A.E. Cross, Mark G. Abel, Peter Ballard, E. Kamon, David R. Gater, James Chih‐Hsin Yang, Pasi A. Jänne, Mireille Cantarini and Peter Johnström and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

James Yates

146 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by James Yates

Since Specialization

Citations

This map shows the geographic impact of James Yates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Yates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Yates more than expected).

Fields of papers citing papers by James Yates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Yates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Yates. The network helps show where James Yates may publish in the future.

Co-authorship network of co-authors of James Yates

This figure shows the co-authorship network connecting the top 25 collaborators of James Yates. A scholar is included among the top collaborators of James Yates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Yates. James Yates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantifying antibody binding: techniques and therapeutic implications 2025 ·mAbs ·(unknown), (unknown), R. E. Duxbury, D. Hall, Glenn A. Burley, (unknown), James Yates, Zahra Rattray	4
2	Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers 2024 ·npj Precision Oncology ·(unknown), Josep V. Forment, (unknown), Dimitris Polychronopoulos, (unknown), Andreas Bender, Violeta Serra, Mark J. O’Connor, James Yates, Krishna C. Bulusu	2
3	Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer. 2024 ·European Journal of Pharmaceutical Sciences ·David Hodson, Hitesh Mistry, James Yates, (unknown), Michael Davies, Leon Aarons, Kayode Ogungbenro	3
4	Long COVID quality of life and healthcare experiences in the UK: a mixed method online survey 2023 ·Quality of Life Research ·(unknown), Ruth Ashton, (unknown), Bethan E. Phillips, James Yates, (unknown), Francesco Ferraro, Tom Bewick, (unknown), Mark A. Faghy	19
5	Manchester Intermittent and Daily diet Type 1 Diabetes App Study (MIDDAS-Type 1): protocol for a randomised feasibility trial of an intermittent and continuous low-energy diet in patients with type 1 diabetes and overweight and obesity 2023 ·BMJ Open ·(unknown), Michelle Harvie, (unknown), (unknown), Womba Mubita, Amanda Hulme, (unknown), James Yates, Suzanne Krizak, (unknown), Basil Issa	1
6	Quantitative Systems Pharmacology and Machine Learning: A Match Made in Heaven or Hell? 2023 ·Journal of Pharmacology and Experimental Therapeutics ·Marcus J. Tindall, L. Cucurull-Sanchez, Hitesh Mistry, James Yates	6
7	Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation 2023 ·Journal of Pharmacology and Experimental Therapeutics ·David Hodson, Hitesh Mistry, James Yates, Paul Farrington, Anna D. Staniszewska, (unknown), Michael Davies, Leon Aarons, Kayode Ogungbenro	2
8	A Spatially Resolved Mechanistic Growth Law for Cancer Drug Development Predicting Tumor Growing Fractions 2022 ·Cancer Research Communications ·(unknown), James Yates, Gianne Derks, (unknown)	1
9	Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model 2022 ·Frontiers in Immunology ·(unknown), Juliana Silva, Oscar Charles, John Booth, S. Y. Amy Cheung, James Yates, Austen Worth, Judith Breuer, Nigel Klein, Persis Amrolia, Paul Veys, Joseph F. Standing	7
10	The ingredients for an antimicrobial mathematical modelling broth 2022 ·International Journal of Antimicrobial Agents ·Marcus J. Tindall, Michael J. Chappell, James Yates	1
11	A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment 2021 ·European Journal of Cancer ·James Yates, S. Y. Amy Cheung	2
12	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression 2018 ·Molecular Cancer Therapeutics ·Yann Wallez, (unknown), Timothy Isaac Johnson, Siang‐Boon Koh, Chiara Fornari, James Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards, Duncan I. Jodrell	79
13	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity breakdown → 2016 ·Clinical Cancer Research ·Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, (unknown), Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross	523
14	Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104 2016 ·Molecular Cancer Therapeutics ·James Yates, Susan Ashton, Darren A.E. Cross, Martine J. Mellor, Steve Powell, Peter Ballard	34
15	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules 2015 ·Molecular Cancer Therapeutics ·Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich	103
16	Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738 2015 ·Scientific Reports ·(unknown), (unknown), James Yates, Paul Jasper, (unknown), John Tolsma, Claus Bendtsen	42
17	Effects of Lumbosacral Manipulation on Isokinetic Strength of the Knee Extensors and Flexors in Healthy Subjects: A Randomized, Controlled, Single-Blind Crossover Trial 2015 ·Journal of Chiropractic Medicine ·(unknown), Arthur J. Nitz, Mark G. Abel, T. Brock Symons, Robert Shapiro, (unknown), James Yates	8
18	Experimental and mathematical analysis of in vitro Pitavastatin hepatic uptake across species 2014 ·Xenobiotica ·Thomas Grandjean, (unknown), (unknown), James Yates, Colm P. O’Donnell	3
19	Assessment of gadoxetate DCE‐MRI as a biomarker of hepatobiliary transporter inhibition 2013 ·NMR in Biomedicine ·(unknown), Simone H. Stahl, James Yates, Neil Woodhouse, J. Gerry Kenna, Huw B. Jones, John C. Waterton, Paul Hockings	32
20	Data reduction in headspace analysis of blood and urine samples for robust bacterial identification 2005 ·Computer Methods and Programs in Biomedicine ·James Yates, Michael J. Chappell, Julian W. Gardner, C.S. Dow, Christopher G. Dowson, (unknown), Frances Bolt, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact